TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company") will promote consumer awareness of the HeartCheckTM PEN handheld ECG device and offer free ECG readings to visitors this weekend (October 26th to 27th) during the ZoomerShow at the Direct Energy Centre in Toronto, Canada.
Attendees of the ZoomerShow will have the opportunity to visit the CardioComm Solutions booth for a hands- on experience with North America's only personal health monitoring device capable of recording and showing an electrocardiogram ("ECG"). Interested visitors will also have an opportunity to have an ECG reading taken using the HeartCheckTM PEN and to receive a free physician ECG interpretation report.
The ZoomerShow is Canada's largest consumer and lifestyle expo for men and women in the 45 plus age range. Health and Wellness is of primary concern to this market segment that now represents 44 percent of Canada's population and controls over 70 percent of Canada's wealth, reports Zoomer.
"The message that we continue to drive home is that consumers need to be empowered to take control of their own health," noted Etienne Grima, CardioComm Solutions' CEO. "The FDA-cleared and Health Canada approved over-the-counter HeartCheckTM PEN and SMART Monitoring solution allows people to do just that. Boomers are a primary target market for us and I cannot think of a better venue to reach this demographic than the ZoomerShow," added Grima.
Participation at the ZoomerShow is part of a series of marketing initiatives launched under the "Take Control" campaign by CardioComm Solutions in recent weeks. The campaign is designed to build consumer and allied health awareness and market demand for the HeartCheckTM PEN and SMART Monitoring service.
Last week CardioComm Solutions attended Vascular 2013 coordinated by the Canadian Cardiovascular Society (CCC) in Montreal, with the opportunity to be present within the booth of Boehringer Ingelheim, one of the exhibiting pharmaceutical companies. The Company demonstrated the HeartCheckTM ECG Monitor and HeartCheckTM ECG PEN to attending delegates for use as a point of care device for ECG reading acquisition. The presentation emphasized the utility of HeartCheckTM devices in the context of atrial fibrillation detection and commencement of anticoagulation therapy for the prevention of stroke.
CardioComm Solutions also confirms Etienne Grima will be one of a distinguished lineup of speakers and a participant in the American Heart Association ("AHA") organized "Heart Innovation Forum" on Friday October 25th 2013, in Chicago, Illinois. The Forum will bring leaders in the life science industry together to discuss innovative ways to accelerate science and to better understand how to treat heart disease and stroke. "I am honoured to have been invited as a panelist by the AHA in this very important forum," said Grima. "Examining state of the art technologies for the detection and treatment of cardiac arrhythmias, and looking at the latest diagnostic and management tools in both consumer and medical markets, aligns perfectly with CardioComm Solutions' core expertise and value proposition."
"We are very encouraged by the growing recognition that CardioComm Solutions has been receiving and the positive feedback on the efficacy of the HeartCheckTM PEN in detecting cardiac arrhythmias," commented Simi Grosman, a member of the Company's Board of Directors. "We will continue to seek venues and public forums from where our 'Take Control' message will best address the critical issues and importance around putting diagnostics and heart health management in the hands of the consumer."
More information regarding the HeartCheckTM products and SMART Monitoring solutions is available at the Company's web site www.theheartcheck.com.
Visit us in Booth 3521 at the ZoomerShow on October 26th and 27th at the Direct Energy Centre, Toronto.
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Canada, with offices in Victoria, B.C.
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425
Forward-looking statements
This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.